Daiichi Sankyo names Hiroyuki Okuzawa as CEO Ruchika Sharma3 Feb 2025 1:30 PM ISTTokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer...
AstraZeneca-Daiichi Sankyo Datopotamab deruxtecan gets USFDA priority review in pretreated EGFR-mutated non-small cell lung cancer Ruchika Sharma14 Jan 2025 2:30 PM ISTDatopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo.
Daiichi Sankyo Datroway approved in Japan for breast cancer Ruchika Sharma29 Dec 2024 12:00 PM ISTTokyo: Daiichi Sankyo's DATROWAY (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor...
AstraZeneca, Daiichi Sankyo voluntarily withdraws datopotamab deruxtecan application in EU for lung cancer Ruchika Sharma25 Dec 2024 11:30 AM ISTCambridge: AstraZeneca and Daiichi Sankyo have voluntarily withdrawn the marketing authorisation application (MAA) in the EU for datopotamab...
USFDA grants priority review to AstraZeneca-Daiichi Sankyo Enhertu for HER2-low, HER2 Ultralow Breast Cancer Ruchika Sharma3 Oct 2024 9:15 AM ISTAstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and...
AstraZeneca-Daiichi Sankyo Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer Ruchika Sharma15 Aug 2024 10:30 AM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for...
AstraZeneca, Daiichi Sankyo Datopotamab deruxtecan application accepted in US for pretreated metastatic HR-positive, HER2-negative breast cancer Ruchika Sharma3 April 2024 12:30 PM ISTAstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the...
AstraZeneca-Daiichi Sankyo application for Datopotamab deruxtecan accepted in US for patients with previously treated advanced nonsquamous non-small cell lung cancer Ruchika Sharma19 Feb 2024 4:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US...
AstraZeneca Enhertu granted priority review in US for metastatic HER2-positive solid tumours Ruchika Sharma31 Jan 2024 12:45 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been...
Esperion, Daiichi Sankyo Europe announce USD 125 million amendment to their collaboration, including resolution of pending litigation Ruchika Sharma4 Jan 2024 4:45 PM ISTAnn Arbor: Esperion Therapeutics, Inc. and Daiichi Sankyo Europe GmbH (DSE), the European headquarter organization of the Japanese pharmaceutical...
Daiichi Sankyo Daichirona for intramuscular injection for booster vaccination approved in Japan as Omicron XBB.1.5-adapted Monovalent mRNA Vaccine against COVID Ruchika Sharma28 Nov 2023 2:30 PM ISTTokyo: Daiichi Sankyo has announced that DAICHIRONA FOR INTRAMUSCULAR INJECTION (DS-5670) for booster vaccination has been approved in Japan as an ...
Daiichi Sankyo Vanflyta approved in EU as First FLT3 Inhibitor specifically for newly Diagnosed FLT3-ITD Positive AML Ruchika Sharma13 Nov 2023 4:30 PM ISTTokyo: Daiichi Sankyo’s VANFLYTA (quizartinib) has been approved in the European Union (EU) for use in combination with standard cytarabine and ...
